Positive topline results from the interim analysis of the ongoing pivotal Phase 3 ALIGN study of atrasentan.
Novartis today announced positive topline results from the interim analysis of the ongoing pivotal Phase 3 ALIGN study of atrasentan, an oral endothelin A receptor antagonist (ERA), in patients with IgAnephropathy (IgAN). The study met its primary efficacy endpoint at…